Scientists investigate how fungus interacts with bacteria to trigger Crohn's...
Scientists have known that bacteria in the gut along with environmental and genetic factors contribute to the debilitating intestinal ailment of Crohn's disease.
View ArticleAlvotech and Cipla Gulf Enter Into a Partnership for the Commercialization of...
REYKJAVIK Iceland and MUMBAI India July 29 2019 PRNewswire Biopharmaceutical company Alvotech and Cipla Gulf FZ LLC "Cipla Gulf" a whollyowned subsidiary of the leading global...
View ArticleMesenchymalStromalCell Therapy Effective LongTerm for Crohn's Disease...
Most patients with Crohn's disease whose perianal fistulas close after allogeneic bone marrowderived mesenchymal stromal cell bmMSC therapy remain fistulafree four years later researchers from the...
View ArticlePredictImmune Closes Series B Funding Round Raising £10M to Further...
New and existing investors demonstrate strong confidence in the developer of unique and pioneering prognostic tools to guide treatment of patients with immunemediated diseasesPredictImmune developers...
View ArticleRedHill Biopharma RDHL TALICIA will dominate newsflow in H219
Edison Investment Research Pharmaceuticals & healthcare RedHill Biopharma RedHill’s Q219 results released on 23 July 2019 described steady progress across its pipeline with TALICIA the...
View ArticleTakeda Reports Strong First Quarter FY2019 Results and Raises Guidance for...
Revenue 849.1 billion yen up 88.8 versus prior year mainly due to acquisition of Shire with solid performance of 14 global growth brandsStrong start with Core Operating Profit of 283.0 billion up 142.3...
View ArticleGenentechs Tecentriq ATEZOLIZUMAB Plus Platinumbased Chemotherapy Reduced...
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally including the...
View ArticleHuman medicines European public assessment report EPAR Inflectra infliximab...
Human medicines European public assessment report EPAR Inflectra infliximab Arthritis PsoriaticSpondylitis AnkylosingColitis UlcerativePsoriasisCrohn DiseaseArthritis Rheumatoid Date of authorisation...
View ArticleSFA Therapeutics Inc. Requests FDA Orphan Drug Designation ODD for SFA001 for...
SFA Therapeutics Inc. announced today that the company has filed an FDA application requesting Orphan Drug Designation ODD for SFA001 the companys novel microbiomebased treatment for human...
View ArticleHave AntiTumor Necrosis Factor Agents Reduced Reoperation Need in Crohn Disease
In Japan the reoperation rate decreased significantly after 2002 when infliximab was introduced in practice.
View ArticlePotential treatment target for Crohn's disease
Crohn's Disease is a form of inflammatory bowel disease IBD in which the body's own immune system attacks the gastrointestinal tract and treatment is focused on controlling the symptoms of the disease...
View ArticleGranulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha...
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha CDw116 or CD116 or CSF2RA Pipeline Review H1 2019SummaryAccording to the recently published report 'Granulocyte Macrophage Colony...
View ArticleTheravance Biopharma Inc TBPH Financial and Strategic SWOT Analysis Review...
Theravance Biopharma Inc TBPH Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by...
View ArticleThreeyear Effectiveness and Safety of Vedolizumab for IBD
This study examined the effectiveness and safety of longterm vedolizumab maintenance therapy in patients with moderatetosevere active ulcerative colitis and Crohn's disease. Alimentary Pharmacology...
View ArticleHuman medicines European public assessment report EPAR Entyvio vedolizumab...
Human medicines European public assessment report EPAR Entyvio vedolizumab Colitis UlcerativeCrohn Disease Date of authorisation 22052014 Revision 13 Status Authorised
View ArticleLandos Biopharma Completes $60 Million Series B Financing
RTW Investments joins existing investor Perceptive Advisors in leading financing with a strong syndicate Proceeds will support two global Phase 2 studies of lead product BT11 for Ulcerative Colitis and...
View ArticleIntegrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 Pipeline Review H1...
Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 Pipeline Review H1 2019SummaryAccording to the recently published report 'Integrin Beta 7 Pipeline Review H1 2019'; Integrin Beta 7 Gut Homing...
View ArticleLandos Biopharma raises $60mm via Series B round
Landos Biopharma Inc. raised $60mm through its Series B round from investors including coleads RTW Investments and Perceptive Advisors along with additional new investors Osage University Partners and...
View ArticleIBDFocused Landos Biopharma Secures $60 Million in Financing
Landos said the funds will be used to advance its lead asset BT11 into global Phase II clinical trials for ulcerative colitis and Crohns disease.
View Article